Lantern Pharma (LTRN) announced the successful completion of targeted enrollment for its Phase 2 HARMONIC clinical trial in Japan. The company enrolled 10 patients ahead of schedule across five clinical sites in Japan, including the National Cancer Center Japan.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN:
- Lantern Pharma Appoints Dr. Schalop to Board
- Lantern reports complete response in pretreated Lymphoma patient with LP-284
- Lantern Pharma issued notice of allowance by EPO for LP-284 patent
- Lantern Pharma launches AI-powered module within RADR platform
- Lantern Pharma Enters ATM Sales Agreement with ThinkEquity